11 results
8-K
EX-99.1
VERV
Verve Therapeutics Inc
8 May 24
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
7:15am
reimbursements.
Research & Development (R&D) Expenses: R&D expenses were $48.4 million for the first quarter of 2024, compared to $47.1 million for the first … quarter of 2023. Stock-based compensation expense included in R&D expenses was $5.6 million and $4.5 million for the first quarter of 2024 and 2023
8-K
EX-99.1
VERV
Verve Therapeutics Inc
27 Feb 24
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
7:45am
the collaboration agreement with Vertex.
R&D Expenses: Research and development (R&D) expenses were $46.8 million for the quarter ended December 31, 2023, and $184.9
8-K
EX-99.1
VERV
Verve Therapeutics Inc
7 Nov 23
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
7:00am
to research services performed under the collaboration agreement with Vertex.
Research & Development (R&D) Expenses: R&D expenses were $43.8 million
8-K
EX-99.1
VERV
Verve Therapeutics Inc
10 Aug 23
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
7:00am
Pharmaceuticals Incorporated. There was no collaboration revenue in the second quarter of 2022.
Research & Development (R&D) Expenses: R&D expenses were $47.3
8-K
EX-99.1
VERV
Verve Therapeutics Inc
15 May 23
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
7:00am
revenue in the first quarter of 2022.
Research & Development (R&D) Expenses: R&D expenses were $47.1 million for the first quarter of 2023, compared
8-K
EX-99.1
a8qe23oa0k57cd1x0
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
8-K
EX-99.1
zwz3t3onz
9 Aug 22
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
6:45am
8-K
EX-99.1
4838hd
10 May 22
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023
6:48am
8-K
EX-99.1
i3o3pgzr2k14s7nk23x
14 Mar 22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
6:49am
8-K
EX-99.1
b1wi4wn 3ka
10 Nov 21
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
6:56am
8-K
EX-99.1
kqv2 dno99
12 Aug 21
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
8:20am
- Prev
- 1
- Next